Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse | Zendy

Pablo Labarga | Zendy; Pablo Barreiro | Zendy; José Antonio López Mira | Zendy; Eugenia Vispo | Zendy; Norma Rallón | Zendy; Karin Neukam | Zendy; Ángela Camacho | Zendy; Antonio Carúz | Zendy; Sonia RodríguezNóvoa | Zendy; Javier Pinilla | Zendy; Antonio Rivero | Zendy; José M. Benito | Zendy; Juan A. Pineda | Zendy; Vincent Soriano | Zendy

Open Access

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

Author(s) -

Pablo Labarga,

Pablo Barreiro,

José Antonio López Mira,

Eugenia Vispo,

Norma Rallón,

Karin Neukam,

Ángela Camacho,

Antonio Carúz,

Sonia RodríguezNóvoa,

Javier Pinilla,

Antonio Rivero,

José M. Benito,

Juan A. Pineda,

Vincent Soriano

Publication year - 2011

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e3283471d83

Subject(s) - ribavirin , medicine , hepatitis c virus , odds ratio , confidence interval , gastroenterology , hepatitis c , hepacivirus , virology , virus , immunology

IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research